Verbindung zur Behandlung von Bakteriellen Infektionen Verschiedener Ätiologie Beim Menschen

Details

Veröffentlichungs-Nr.

EP4067336

Aktenzeichen

EP21020218

Anmeldetag

19. April 2021

Veröffentlichung

21. Mai 2025

Erteilung

21. Mai 2025

Rechtsraum

EP

IPC

C07C205/23C07C237/04A61P31/04

Abstract

The invention relates to a novel compound manufactured with the procedure of synthesis of bouncing Carvacrol and Lidocaine into one stable compound. Use of the compound as an active compound/potent antimicrobial for the treatment of bacterial infections in humans caused by pathogens resistant to antibiotics, such as Methicillin-resistant Staphylococcus aureus (MRSA), Streptococcus faecalis, Mycobacterium tuberculosis, Escherichia spp. E. coli, Salmonella spp. Pasteurella spp., Corynebacterium spp., Bacillus spp., Bacillus anthracis, Clostridium spp., Spherophorus spp., Candida spp., Trichophyton spp., Microsporum spp., Mycobacterium spp., Vibrio spp., Cryp-tosporidium spp., Microsporidia spp., Listeria monocytogenes, Lawsonia intracellu-laris, Treponema dysenteriae, Enterococcus spp., Haemophilus spp., Campylobacter spp., Chlamydia spp., Brucella spp., and other pathogenic bacterial species.

Anmelder

Firma

Tesla Bioscience ad Banja Luka

Land

🇧🇦 Bosnien und Herzegowina

Fachgebiete